Intravenous antigen administration as a therapy for autoimmune demyelinating disease

Michael K. Racke, Jeffrey M. Critchfield, Laura Quigley, Barbara Cannella, Cedric S. Raine, Henry F. McFarland, Michael J. Lenardo

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Experimental allergic encephalomyelitis is a prototypic autoimmune disease characterized by central nervous system inflammation and demyelination. Previously, we demonstrated that intravenous administration of high doses of myelin basic protein abrogated the clinical and pathological signs of experimental allergic encephalomyelitis by causing the deletion of encephalitogenic, CD4+, myelin basic protein-specific T cells through antigen-induced programmed cell death. In the present study, we further characterized the ability of intravenous antigen administration to attenuate an immune response by myelin basic protein-reactive encephalitogenic T cells. We demonstrated that multiple injections of myelin basic protein are required to achieve a therapeutic response, and that this form of therapy is effective even after prolonged chronic disease. These studies showed that although interleukin-2-stimulated cell cycling is an important factor leading to T- cell death, the administration of exogenous interleukin-2 with antigen can result in the agglavation of clinical disease compared to administration of antigen alone. More importantly, administration of myelin basic protein alone without interleukin-2 was sufficient to reduce autoreactive T cells and clinical disease in experimental autoimmune encephalomyelitis. Our experiments support the rationale for antigen-specific therapy aimed at inducing the programmed death of autoreactive T cells in autoimmune diseases, potentially including the human demyelinating disease multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)46-56
Number of pages11
JournalAnnals of Neurology
Volume39
Issue number1
DOIs
StatePublished - 1996

Fingerprint

Myelin Basic Protein
Demyelinating Diseases
Intravenous Administration
Autoimmune Diseases
Autoimmune Experimental Encephalomyelitis
T-Lymphocytes
Antigens
Interleukin-2
Cell Death
Therapeutics
Multiple Sclerosis
Chronic Disease
Central Nervous System
Inflammation
Injections

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Racke, M. K., Critchfield, J. M., Quigley, L., Cannella, B., Raine, C. S., McFarland, H. F., & Lenardo, M. J. (1996). Intravenous antigen administration as a therapy for autoimmune demyelinating disease. Annals of Neurology, 39(1), 46-56. https://doi.org/10.1002/ana.410390108

Intravenous antigen administration as a therapy for autoimmune demyelinating disease. / Racke, Michael K.; Critchfield, Jeffrey M.; Quigley, Laura; Cannella, Barbara; Raine, Cedric S.; McFarland, Henry F.; Lenardo, Michael J.

In: Annals of Neurology, Vol. 39, No. 1, 1996, p. 46-56.

Research output: Contribution to journalArticle

Racke, MK, Critchfield, JM, Quigley, L, Cannella, B, Raine, CS, McFarland, HF & Lenardo, MJ 1996, 'Intravenous antigen administration as a therapy for autoimmune demyelinating disease', Annals of Neurology, vol. 39, no. 1, pp. 46-56. https://doi.org/10.1002/ana.410390108
Racke MK, Critchfield JM, Quigley L, Cannella B, Raine CS, McFarland HF et al. Intravenous antigen administration as a therapy for autoimmune demyelinating disease. Annals of Neurology. 1996;39(1):46-56. https://doi.org/10.1002/ana.410390108
Racke, Michael K. ; Critchfield, Jeffrey M. ; Quigley, Laura ; Cannella, Barbara ; Raine, Cedric S. ; McFarland, Henry F. ; Lenardo, Michael J. / Intravenous antigen administration as a therapy for autoimmune demyelinating disease. In: Annals of Neurology. 1996 ; Vol. 39, No. 1. pp. 46-56.
@article{e6d75c2885944d818bad524d0cf9d538,
title = "Intravenous antigen administration as a therapy for autoimmune demyelinating disease",
abstract = "Experimental allergic encephalomyelitis is a prototypic autoimmune disease characterized by central nervous system inflammation and demyelination. Previously, we demonstrated that intravenous administration of high doses of myelin basic protein abrogated the clinical and pathological signs of experimental allergic encephalomyelitis by causing the deletion of encephalitogenic, CD4+, myelin basic protein-specific T cells through antigen-induced programmed cell death. In the present study, we further characterized the ability of intravenous antigen administration to attenuate an immune response by myelin basic protein-reactive encephalitogenic T cells. We demonstrated that multiple injections of myelin basic protein are required to achieve a therapeutic response, and that this form of therapy is effective even after prolonged chronic disease. These studies showed that although interleukin-2-stimulated cell cycling is an important factor leading to T- cell death, the administration of exogenous interleukin-2 with antigen can result in the agglavation of clinical disease compared to administration of antigen alone. More importantly, administration of myelin basic protein alone without interleukin-2 was sufficient to reduce autoreactive T cells and clinical disease in experimental autoimmune encephalomyelitis. Our experiments support the rationale for antigen-specific therapy aimed at inducing the programmed death of autoreactive T cells in autoimmune diseases, potentially including the human demyelinating disease multiple sclerosis.",
author = "Racke, {Michael K.} and Critchfield, {Jeffrey M.} and Laura Quigley and Barbara Cannella and Raine, {Cedric S.} and McFarland, {Henry F.} and Lenardo, {Michael J.}",
year = "1996",
doi = "10.1002/ana.410390108",
language = "English (US)",
volume = "39",
pages = "46--56",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Intravenous antigen administration as a therapy for autoimmune demyelinating disease

AU - Racke, Michael K.

AU - Critchfield, Jeffrey M.

AU - Quigley, Laura

AU - Cannella, Barbara

AU - Raine, Cedric S.

AU - McFarland, Henry F.

AU - Lenardo, Michael J.

PY - 1996

Y1 - 1996

N2 - Experimental allergic encephalomyelitis is a prototypic autoimmune disease characterized by central nervous system inflammation and demyelination. Previously, we demonstrated that intravenous administration of high doses of myelin basic protein abrogated the clinical and pathological signs of experimental allergic encephalomyelitis by causing the deletion of encephalitogenic, CD4+, myelin basic protein-specific T cells through antigen-induced programmed cell death. In the present study, we further characterized the ability of intravenous antigen administration to attenuate an immune response by myelin basic protein-reactive encephalitogenic T cells. We demonstrated that multiple injections of myelin basic protein are required to achieve a therapeutic response, and that this form of therapy is effective even after prolonged chronic disease. These studies showed that although interleukin-2-stimulated cell cycling is an important factor leading to T- cell death, the administration of exogenous interleukin-2 with antigen can result in the agglavation of clinical disease compared to administration of antigen alone. More importantly, administration of myelin basic protein alone without interleukin-2 was sufficient to reduce autoreactive T cells and clinical disease in experimental autoimmune encephalomyelitis. Our experiments support the rationale for antigen-specific therapy aimed at inducing the programmed death of autoreactive T cells in autoimmune diseases, potentially including the human demyelinating disease multiple sclerosis.

AB - Experimental allergic encephalomyelitis is a prototypic autoimmune disease characterized by central nervous system inflammation and demyelination. Previously, we demonstrated that intravenous administration of high doses of myelin basic protein abrogated the clinical and pathological signs of experimental allergic encephalomyelitis by causing the deletion of encephalitogenic, CD4+, myelin basic protein-specific T cells through antigen-induced programmed cell death. In the present study, we further characterized the ability of intravenous antigen administration to attenuate an immune response by myelin basic protein-reactive encephalitogenic T cells. We demonstrated that multiple injections of myelin basic protein are required to achieve a therapeutic response, and that this form of therapy is effective even after prolonged chronic disease. These studies showed that although interleukin-2-stimulated cell cycling is an important factor leading to T- cell death, the administration of exogenous interleukin-2 with antigen can result in the agglavation of clinical disease compared to administration of antigen alone. More importantly, administration of myelin basic protein alone without interleukin-2 was sufficient to reduce autoreactive T cells and clinical disease in experimental autoimmune encephalomyelitis. Our experiments support the rationale for antigen-specific therapy aimed at inducing the programmed death of autoreactive T cells in autoimmune diseases, potentially including the human demyelinating disease multiple sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0030071366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030071366&partnerID=8YFLogxK

U2 - 10.1002/ana.410390108

DO - 10.1002/ana.410390108

M3 - Article

VL - 39

SP - 46

EP - 56

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -